Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew C Hsieh

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Cancer Cell|October 11, 2017
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF SignalingEric G Bluemn, Ilsa M Coleman, Jared M Lucas, et al.
Nature Communications|November 5, 2021
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancerMeixia Che, Aashi Chaturvedi, Sarah A Munro, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Clinical Genitourinary Cancer|September 26, 2022
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial CarcinomaRafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Cancer Cell|October 11, 2017
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF SignalingEric G Bluemn, Ilsa M Coleman, Jared M Lucas, et al.
Nature Communications|November 5, 2021
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancerMeixia Che, Aashi Chaturvedi, Sarah A Munro, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Clinical Genitourinary Cancer|September 26, 2022
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial CarcinomaRafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, et al.
Pageof 7